Sign Up for a Free Account

This is an image preview.
Start a Free Account
to view the full image.

Sign Up for a Free Account For information on discounts, see Plans & Pricing

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

FDA-approved disease-modifying therapies for multiple sclerosis

Since 1993, 20 disease-modifying therapies have been approved by the FDA for the treatment of relapsing multiple sclerosis. Ocrelizumab remains the only therapy approved for primary progressive multiple sclerosis. Ublituximab is anticipated to be available in early 2023 for the treatment of relapsing multiple sclerosis. Four Bruton tyrosine kinase (BTK) inhibitors are in phase III clinical trials, including for relapsing and progressive indications. (Contributed by Dr. Andrew Wolf.)